### Edgar Filing: THERMOGENESIS CORP - Form 8-K

# THERMOGENESIS CORP Form 8-K November 30, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 24, 2004

THERMOGENESIS CORP.

(Exact name of registrant as specified in its charter)

> 2711 Citrus Road Rancho Cordova, California 95742

(Address and telephone number of principal executive offices) (Zip Code)

(916) 858-5100

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 - Other Events

Item 8.01 Other Events.

On November 24, 2004, ThermoGenesis Corp. (the "Company") provided update on a press release on its Thrombin Processing Device ("TPD") and DAC System for the semi-automated separation of whole blood. The FDA determined that the TPD is not substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976 or to any device which has been reclassified into Class I or Class II and therefore, the TPD has been classified by statute into Class III (Pre-Market Approval ("PMA")). The FDA has reviewed the DAC System 510(k)

## Edgar Filing: THERMOGENESIS CORP - Form 8-K

submission for the semi-automated separation of whole blood and freezing of blood components and requires additional information to complete its determination of substantial equivalency to devices marketed in interstate commerce. ThermoGenesis has recently provided additional information for the FDA's review. Additional information can be found on the press release attached as Exhibit 99.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Exhibit Description	
99	Press Release Updating Regulatory Cl	earance Status.
	for Autologous Thrombin Processing De	vice (TPD(TM))
	and the DAC(TM) System	

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

> THERMOGENESIS CORP., a Delaware Corporation

Dated:	November 29,	2004	/s/ Renee M. Ruecker
			Renee Ruecker,
			Chief Financial Officer

#### EXHIBIT INDEX

Exhibit No.	Description
99	Press Release dated November 24, 2004 titled
	"Thermogenesis Updates Regulatory Clearance Status
	for Autologous Thrombin Processing Device (TPD(TM))
	and the DAC(TM) System "